Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-guided bladder-preserving treatment study in high-risk NMIBC
ChiCTR2400093839Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin, tislelizumab, bcg vaccine, cisplatin and epirubicin in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 1-year recurrence-free survival rate. Started Aug 2024; status: recruiting.
02
Drugs
disitamab vedotintislelizumabbcg vaccinecisplatinepirubicin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400093839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093839.